Summit Therapeutics’ $75 Million Rights Offering

Olshan Frome Wolosky LLP represented Summit Therapeutics in the offering.

Summit Therapeutics Inc. (NASDAQ: SMMT) executed its rights offering of up to 14,312,977 shares of its common stock, par value $0.01 with an aggregate offering value of up to $75,000,000. 

Summit Therapeutics Inc. (NASDAQ: SMMT) is a clinical-stage drug discovery and development company.

Olshan Frome Wolosky LLP represented Summit Therapeutics with a team led by corporate partner Adam Finerman (Picture) with assistance from corporate associates Scott Kilian-Clark and Zachary Freedman and tax partner Mark Limardo.

Involved fees earner: Adam Finerman – Olshan Frome Wolosky; Zachary Freedman – Olshan Frome Wolosky; Scott Kilian-Clark – Olshan Frome Wolosky; Mark Limardo – Olshan Frome Wolosky;

Law Firms: Olshan Frome Wolosky;

Clients: Summit Therapeutics Plc;

Author: Martina Bellini